dantrolene has been researched along with Myalgia in 3 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
Myalgia: Painful sensation in the muscles.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dantrolene has shown promising results in controlling muscle symptoms in individuals with ERM, however, its use in children remains poorly documented." | 5.91 | Oral Dantrolene Reduces Myalgia and Hyperckemia in a Child with RYR1-Related Exertional Myalgia/Rhabdomyolysis. ( Aschoff, CAM; de Lima Silva, EV; de Souza, CFM; Donis, KC; Machado, FRC; Poswar, FO; Saute, JAM; Simão Medeiros, L, 2023) |
| "Dantrolene median dose was 50 (25-400) and 200 (25-400) mg·day -1 in responders and nonresponders, respectively." | 1.91 | Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability. ( Ibarra Moreno, CA; Jungbluth, H; Kraeva, N; Riazi, S; Voermans, NC; Zvaritch, E, 2023) |
| "Dantrolene has shown promising results in controlling muscle symptoms in individuals with ERM, however, its use in children remains poorly documented." | 1.91 | Oral Dantrolene Reduces Myalgia and Hyperckemia in a Child with RYR1-Related Exertional Myalgia/Rhabdomyolysis. ( Aschoff, CAM; de Lima Silva, EV; de Souza, CFM; Donis, KC; Machado, FRC; Poswar, FO; Saute, JAM; Simão Medeiros, L, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ibarra Moreno, CA | 1 |
| Kraeva, N | 1 |
| Zvaritch, E | 1 |
| Jungbluth, H | 1 |
| Voermans, NC | 1 |
| Riazi, S | 1 |
| de Lima Silva, EV | 1 |
| Donis, KC | 1 |
| Machado, FRC | 1 |
| Simão Medeiros, L | 1 |
| Aschoff, CAM | 1 |
| de Souza, CFM | 1 |
| Poswar, FO | 1 |
| Saute, JAM | 1 |
| Butala, BN | 1 |
| Kang, A | 1 |
| Guron, J | 1 |
| Brandom, BW | 1 |
3 other studies available for dantrolene and Myalgia
| Article | Year |
|---|---|
Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability.
Topics: Dantrolene; Drug-Related Side Effects and Adverse Reactions; Fatigue; Halothane; Humans; Malignant H | 2023 |
Oral Dantrolene Reduces Myalgia and Hyperckemia in a Child with RYR1-Related Exertional Myalgia/Rhabdomyolysis.
Topics: Child; Child, Preschool; Dantrolene; Humans; Muscles; Myalgia; Rhabdomyolysis; Ryanodine Receptor Ca | 2023 |
Long term oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual.
Topics: Adult; Chronic Pain; Creatine Kinase; Dantrolene; Female; Humans; Malignant Hyperthermia; Muscle Cra | 2016 |